Eagle’s minimum essential medium (EMEM), fetal bovine serum (FBS), and 2′-7′-dichloro-fluorescin diacetate (DCF-DA) were purchased from Invitrogen Corp. (Carlsbad, CA); p-nitrophenyl phosphate [pNPP], HEPES, trypsin, AA, lucigenin, β-glycerphosphate, chymostatin, 3,4-DCI, E-64, leupeptin, pepstatin A, phenylmethylsulfonyl fluoride (PMSF), N-acetylcysteine (NAC), and Na3VO4 from Sigma-Aldrich (St. Louis, MO); and antibodies against phospho-p42/44 MAPK (ERK1/2), phospho-JNK, phospho-p38, phospho-Akt, and Rac1 from Cell Signaling Technology Inc. (Beverly, MA). Antibodies against glyceraldehyde-3-phosphodehydrogenase (G3PD); p22phox, p47phox, p67phox, and p40phox; P-Tyr857 PDGFR; PDGFR, and horseradish peroxidase–conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The enhanced chemiluminescence (ECL) system components were from Pierce Biotechnology (Rockford, IL). Nitrocellulose membrane (Hybond-ECL) was from Amersham Biosciences Inc. (Piscataway, NJ).